Effect of high level of androgen on Polycystic ovary syndrome (PCOS)

DOI:

https://doi.org/10.36371/port.2024.special.4

Authors

  • Baqer J. Hasan College of veterinary medicine, Baghdad University, Baghdad, Iraq.
  • Sumaya L. M. Shams Al-Dean College of veterinary medicine, Middle Technical University, Baghdad, Iraq.
  • Zainab Fadhil Abbas College of medical technology, Uruk University, Baghdad, Iraq.

A multifactorial endocrine condition, polycystic ovarian syndrome (PCOS) is typified by anovulation, hyperandrogenism, and polycystic ovarian shape. In the current study, a number of women with PCOS underwent testing to determine the impact of the androgen  hormone on PCOS. Upon follow-up, it was discovered that the majority of the samples, ranging in age from (49), (28), (26), (40), (24), (15), (20), (17), and (25) all had androgen  levels that were the same—less than 1.00 ng/ml. This suggests that the sample's and all ages' androgen  levels are below the normal level, which is believed to be between 2 and 8 ng/ml. At age 24, the percentage of androgen  was calculated to be 1.06 ng/ml, which is low in comparison to the normal level of androgen . The sample, which comprises people in the ages of (20) and (27), had estimated androgen  percentages of 1.02 ng/ml and 1.49 ng/ml, respectively. We note some minor variations in the analytical comparison between the samples, but despite this The proportion in this sample is nevertheless less than its true level, which is probably to be between (2-8), Since every member of the sample has polycystic ovarian disease, there is a specific malfunction in the way this sample's body operates, necessitating the development of solutions and early identification. about the illness using a variety of analyses to prevent contracting other fatal illnesses.

Keywords:

Polycystic ovarian syndrome (PCOS), Hyperandrogenism, Endocrine condition, Anovulation Androgen levels

[1] Ashraf, et al ,(2019). Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: a review. The Egyptian Journal of Medical Human Genetics, 20(25): 3-10.

[2] Elleithy, et al , (2022). Spirulina therapeutic potentiality in polycystic ovarian syndrome management using DHEA-induced rat model. European Review for Medical and Pharmacological Sciences, (26): 2740-2754.

[3] Yousouf, et al, (2012). Polycystic Ovarian Syndrome: Clinical Correlation with Biochemical Status. The Scientific Research, (3): 245-248.

[4] Didier, et al, (2014). European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group’s Questionnaire. European Journal of Endocrinology, 171(4): 489–498.

[5] Sirmans and Pate, (2013). Epidemiology, diagnosis, and management of polycystic ovary syndrome. Dove press journal: Clinical Epidemiology, (6): 1-13.

[6] Alemany, (2022). The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health. International Journal of Molecular Sciences, (23): 11952.

[7] Kumarendran, et al, (2018). Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database. The Plose medicine, 15(3): 1-20.

[8] lentscher and Decherney, (2021). Clinical Presentation and Diagnosis of Polycystic Ovarian Syndrome. Clinical obstetrics and gunecology, 64(1): 3-11.

[9] Sadeghi, et al, (2021). Polycystic Ovary Syndrome: A Comprehensive Review ofPathogenesis, Management, and Drug Repurposing. International Journal of Molecular Sciences, (23): 583.

[10] Paris and Bertoldo, (2019). The Mechanism of Androgen Actions in PCOS Etiology. medical sciences, 89(7).

[11] Ndefo, et al, (2013). Polycystic Ovary Syndrome A Review of Treatment Options With a Focus on Pharmacological Approaches. The P&T, 38(6): 336.

[12] Alsaadi and Mohamad,(2019). Prevalence of hyperandrogenism in Iraqi women with polycystic ovary syndrome. Iraqi journal of science, 60(12): 2600-2608.

[13] Franks and Hardy, (2018). Androgen Action in the Ovary. Frontiers in endocrinology, 9(452).

[14] Bednarska and Agnieszka, (2017). The pathogenesis and treatment of polycystic ovary syndrome: What’s new?.The Advances in Clinical and Experimental Medicine, 26(2):359–367.

[15] Lebbe and Woodruff, (2013). Involvement of androgens in ovarian health and disease. Molecular Human Reproduction, 19(12): 828–837.

[16] Davison and Davis, (2003). Androgens in women. Journal of Steroid Biochemistry & Molecular Biology, (85): 363-366.

[17] Gurevich, (2022). PCOS and other Possible Causes of Hyperandrogenism,Verywell Health, (18).

[18] Burger, (2002). Androgen production in women, sciencedirect, 77(4): 3-5.

[19] Walters, et al, (2019). Androgens and ovarian function: translation from basic discovery research to clinical impact, Journal of endocrinology, 242(2): 23-50.

[20] Kanbour and Dobs, (2022). Women with Polycystic Ovarian Syndrome: Pathophysiology and Controversies, Clinical Research and Therapeutics, 3(1).

Hasan, B. J. ., Shams Al-Dean, S. L. M. ., & Abbas, Z. F. . (2024). Effect of high level of androgen on Polycystic ovary syndrome (PCOS). Journal Port Science Research, 7(issue), 25–29. https://doi.org/10.36371/port.2024.special.4

Downloads

Download data is not yet available.